Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.

Journal of medicinal chemistry - 14 Apr 2016

Zhan Peng, Pannecouque Christophe, De Clercq Erik, Liu Xinyong

Abstract excerpt

The early effectiveness of combinatorial antiretroviral therapy (cART) in the treatment of HIV infection has been compromised to some extent by rapid development of multidrug-resistant HIV strains, poor bioavailability, and cumulative toxicities, and so there is a need for alternative strategies of antiretroviral drug discovery and additional therapeutic agents with novel action modes or targets. From this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Chemistry, Pharmaceutical
Share to Chemoprevention

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Drug Discovery

Share to HIV Protease Inhibitors

Share to Prodrugs

Share to Solubility

Source

Identifiers

PMID: 26509831
DOI: 10.1021/acs.jmedchem.5b00497

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.PMID 26509831Read ↗

Current and Novel Inhibitors of HIV ProteaseSemantic proximity Read ↗

“Old Dogs with New Tricks”: exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targetsSemantic proximity Read ↗

Non-peptidic HIV protease inhibitors.Semantic proximity Read ↗

Therapy of HIV Infection: Current Approaches and ProspectsSemantic proximity Read ↗

2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.Semantic proximity Read ↗

Current HIV therapeutics: mechanistic and chemical determinants of toxicity.Semantic proximity Read ↗

Design of novel HIV-1 protease inhibitors with favorable oral properties using a virtual screening and lead optimization approachSemantic proximity Read ↗

Structure, Synthesis and Inhibition Mechanism of Nucleoside Analogues as HIV‐1 Reverse Transcriptase Inhibitors (NRTIs)Semantic proximity Read ↗

Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.Semantic proximity Read ↗

Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistance.Semantic proximity Read ↗

A N-propionylsulfonamide prodrug of K-5a2 provided improved aqueous solubility and hERG inhibitionSemantic proximity Read ↗

P1-substituted symmetry-based human immunodeficiency virus protease inhibitors with potent antiviral activity against drug-resistant viruses.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.